Skip to main content

Advertisement

SpringerLink
Log in

Surgery for Peritoneal Mesothelioma

  • Malignant Mesothelioma
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Malignant peritoneal mesothelioma (MPM) is a rare, progressive, and ultimately fatal disease in almost all afflicted individuals. MPM is a cancer that arises diffusely from the serosa of the abdominal cavity and progresses almost exclusively in this region; understanding its characteristic tumor biology has been the reasoning behind the development of treatment strategies designed to control disease progression in the peritoneum. This principally includes operative cytoreduction and hyperthermic intra-operative perfusion of intraperitoneal chemotherapy (HIPEC). This approach has been administered either alone or in combination with early postoperative intraperitoneal chemotherapy (EPIC), or as a component of a more protracted multimodal approach employing initial debulking surgery, intraperitoneal chemotherapy, and whole abdominal radiotherapy. Median overall survivals of up to 7 years have been observed in series of patients selected for operative cytoreduction and HIPEC. Factors associated with good outcome are female gender, age less or equal to 60 years, and the ability to achieve a complete extirpation of all gross peritoneal disease. In patients with symptomatic ascites, complete palliation is achieved in almost all cases. However, this treatment strategy is not without complications and carries a morbidity of 25% and mortality up to 7%. Despite these risks, the best overall survival data have been associated with this surgical approach. At our institution, we advocate cytoreduction and HIPEC as the standard management for patients with MPM for whom operative cytoreduction appears possible and safe. We believe this treatment approach should be considered as the standard of care for patients with MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–88.

    Article  PubMed  Google Scholar 

  2. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.

    Article  PubMed  Google Scholar 

  3. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.

    Article  PubMed  CAS  Google Scholar 

  4. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol. 2004;159:107–12.

    Article  PubMed  Google Scholar 

  5. Rivera Z, Strianese O, Bertino P, et al. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008;14:316–21.

    Article  PubMed  Google Scholar 

  6. Acherman YI, Welch LS, Bromley CM, et al. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269–73.

    PubMed  Google Scholar 

  7. Alexander HR, Hanna N, Pingpank JF. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res. 2007;134:343–55.

    PubMed  CAS  Google Scholar 

  8. Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356–62.

    Article  PubMed  CAS  Google Scholar 

  9. Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93.

    Article  PubMed  CAS  Google Scholar 

  10. Yan TD, Deraco M, Baratti D et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.This paper represents the first multi-institutional analysis of survival and factors related to survival of patients with MPM

    Google Scholar 

  11. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    Article  PubMed  CAS  Google Scholar 

  12. Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol. 2008;191:814–25.

    Article  PubMed  Google Scholar 

  13. Reuter K, Raptopoulos V, Reale F, et al. Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. AJR Am J Roentgenol. 1983;140:1189–94.

    PubMed  CAS  Google Scholar 

  14. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.

    Article  PubMed  Google Scholar 

  15. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98:268–72.

    Article  PubMed  Google Scholar 

  16. Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21. xi.

    Article  PubMed  Google Scholar 

  17. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.

    Article  PubMed  Google Scholar 

  18. Varghese S, Chen Z, Bartlett DL et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117:361–71.This paper describes the inhibition of two important molecular pathways in MPM in vitro and relates these pathways to survival differences in patients with MPM

    Google Scholar 

  19. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317–31.

    PubMed  Google Scholar 

  20. Cerruto CA, Brun EA, Chang D, et al. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.

    PubMed  Google Scholar 

  21. Antman K, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977–81.

    Article  PubMed  CAS  Google Scholar 

  22. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    Article  PubMed  CAS  Google Scholar 

  23. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:676–81.

    Article  PubMed  CAS  Google Scholar 

  24. Antman K, Pomfret F, Aisner J, et al. Peritoneal mesothelioma: Natural history and response to chemotherapy. J Clin Oncol. 1983;1:386.

    PubMed  CAS  Google Scholar 

  25. Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    Article  PubMed  CAS  Google Scholar 

  26. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.

    Article  PubMed  CAS  Google Scholar 

  27. Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49–54.

    Article  PubMed  CAS  Google Scholar 

  28. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649–71.

    Article  PubMed  Google Scholar 

  29. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.

    Article  PubMed  Google Scholar 

  30. Barranco SC. Review of the survival and cell kinetics of adriamycin (NSC- 123127) on mammalian cells. Cancer Chemotherapy Reports Part 3. 1975;6(2):147–52.

    CAS  Google Scholar 

  31. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.

    Article  PubMed  Google Scholar 

  32. Sugarbaker PH, Yan TD, Stuart OA et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006.

  33. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.

    Article  PubMed  Google Scholar 

  34. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:948–53.

    Article  PubMed  CAS  Google Scholar 

  35. Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003.

    PubMed  CAS  Google Scholar 

  36. Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–12.

    Article  PubMed  CAS  Google Scholar 

  37. Kluger MD, Taub RN, Hesdorffer M, et al. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36:997–1003.

    PubMed  CAS  Google Scholar 

  38. Blackham AU, Shen P, Stewart JH et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:2720–7.This paper provides the most recent data regarding the survival of patients with MPM as it relates to the choice of intraperitoneal chemotherapeutic agent

    Google Scholar 

  39. Yan TD, Deraco M, Elias D et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2010. This paper proposes a complete staging system for MPM, including the importance of lymph node metastasis in patient survival

  40. Baratti D, Kusamura S, Cabras AD, et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53.

    Article  PubMed  Google Scholar 

  41. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    Article  PubMed  CAS  Google Scholar 

  42. Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–49.

    Article  PubMed  Google Scholar 

  43. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.

    Article  PubMed  CAS  Google Scholar 

  44. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.

    Article  PubMed  CAS  Google Scholar 

  45. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Maryland Medical Center, 22 S. Greene St., Baltimore, MD, 21201, USA

    Keli M. Turner MD

  2. Department of Surgery, University of Maryland School of Medicine, 22 S. Greene Street, Baltimore, MD, 21201, USA

    Sheelu Varghese PhD

  3. Department of Surgery, University of Maryland School of Medicine, 22 S. Greene St., S4B05A, Baltimore, MD, 21201, USA

    H. Richard Alexander Jr. MD

Authors
  1. Keli M. Turner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheelu Varghese PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Richard Alexander Jr. MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Richard Alexander Jr. MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, K.M., Varghese, S. & Alexander, H.R. Surgery for Peritoneal Mesothelioma. Curr. Treat. Options in Oncol. 12, 189–200 (2011). https://doi.org/10.1007/s11864-011-0151-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0151-7

Keywords

Search

Navigation